Description: Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.
Home Page: valneva.com
6 rue Alain Bombard
Saint-Herblain,
44800
France
Phone:
33 2 28 07 37 10
Officers
Name | Title |
---|---|
Mr. Thomas Lingelbach | Chairman of the Management Board, Pres & CEO |
Mr. Franck Grimaud MBA | Director Gen., Chief Bus. Officer & Member of Management Board |
Mr. Frederic Jacotot | VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board |
Dr. Juan-Carlos Jaramillo M.D. | Chief Medical Officer & Member of the Management Board |
Mr. Peter Buhler | CFO & Management Board Member |
Mr. Perry Celentano | Interim Chief Operating Officer |
Ms. Dipal Patel | Chief Commercial Officer & Member of Management Board |
Mr. Joshua Drumm Ph.D. | VP of Investor Relations |
Ms. Laetitia Bachelot-Fontaine | VP of Global Communications & European Investor Relations |
Mr. Gerald Strohmaier | VP of Human Resource |
Exchange: PINK
Country: US
Currency: US Dollar ($)
Forward PE: | 0 |
---|---|
Trailing PE: | 7.4891 |
Price-to-Book MRQ: | 5.6283 |
Price-to-Sales TTM: | 2.2307 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 762 |